--- title: "Janus Living | 10-Q: FY2026 Q1 Revenue: USD 4.712 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/286813119.md" datetime: "2026-05-18T20:04:27.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286813119.md) - [en](https://longbridge.com/en/news/286813119.md) - [zh-HK](https://longbridge.com/zh-HK/news/286813119.md) --- # Janus Living | 10-Q: FY2026 Q1 Revenue: USD 4.712 M Revenue: As of FY2026 Q1, the actual value is USD 4.712 M. EPS: As of FY2026 Q1, the actual value is USD -2.14. EBIT: As of FY2026 Q1, the actual value is USD -2.237 M. ### Consolidated Financial Performance (Dollars in thousands) #### Revenue - Revenues for Janus Living, Inc. were $4,712 for the 13 weeks ended March 28, 2026, a decrease from $4,849 for the 13 weeks ended March 29, 2025 . #### Operational Metrics - Cost of revenues was $1,138 for the 13 weeks ended March 28, 2026, down from $2,923 in the prior year period . - Gross profit increased to $3,574 for the 13 weeks ended March 28, 2026, from $1,926 for the same period in 2025 . - Selling, General and Administrative Expenses increased to $6,317 for the 13 weeks ended March 28, 2026, from $3,872 for the same period in 2025 . - Operating loss was - $2,743 for the 13 weeks ended March 28, 2026, compared to - $1,946 for the prior year period . - Interest expense, net, was - $506 for the 13 weeks ended March 28, 2026, a decrease from - $720 for the same period in 2025 . - Net loss from continuing operations was - $271,316 for the 13 weeks ended March 28, 2026, significantly higher than - $1,912 for the same period in 2025 . - Net loss from discontinued operations was - $177 for the 13 weeks ended March 28, 2026, compared to - $480 for the same period in 2025 . - Net loss was - $271,493 for the 13 weeks ended March 28, 2026, compared to - $2,392 for the same period in 2025 . #### Unique Metrics - Unrealized loss on cryptocurrency assets was - $348,301 for the 13 weeks ended March 28, 2026, compared to $0 in the prior year . - Realized (loss) gain on exchange transactions was - $6,082 for the 13 weeks ended March 28, 2026, compared to $973 for the same period in 2025 . ### Segment Performance (Dollars in thousands) #### Fintech Segment - Revenue was $4,712 for the 13 weeks ended March 28, 2026, compared to $4,849 for the 13 weeks ended March 29, 2025 . - Gross profit was $3,574, representing a 75.9% gross profit percentage, for the 13 weeks ended March 28, 2026, up from $1,926 (47.0% gross profit percentage) for the same period in 2025 . - Operating loss was - $1,638 for the 13 weeks ended March 28, 2026, compared to - $138 for the same period in 2025 . - Depreciation and amortization was $888 for the 13 weeks ended March 28, 2026, compared to $728 for the same period in 2025 . - Net income (loss) before income taxes was $1,631 for the 13 weeks ended March 28, 2026, compared to $543 for the same period in 2025 . #### Biotechnology Segment (Discontinued Operations) - Revenue and gross profit were $0 for both periods . - Operating loss was - $177 for the 13 weeks ended March 28, 2026, compared to - $540 for the same period in 2025 . - Depreciation and amortization was $0 for the 13 weeks ended March 28, 2026, compared to $482 for the same period in 2025 . - Net income (loss) before income taxes was - $177 for the 13 weeks ended March 28, 2026, compared to - $540 for the same period in 2025 . #### Corporate and Other Segment - Revenue and gross profit were $0 for both periods . - Operating loss was - $1,105 for the 13 weeks ended March 28, 2026, compared to - $1,268 for the same period in 2025 . - Net income (loss) before income taxes was - $358,028 for the 13 weeks ended March 28, 2026, compared to - $1,690 for the same period in 2025 . ### Liquidity and Capital Resources (Dollars in thousands) #### Cash Flow - Net cash used in operating activities was - $12,293 for the 13 weeks ended March 28, 2026, compared to - $1,423 for the same period in 2025 . - Net cash provided by financing activities was $8,516 for the 13 weeks ended March 28, 2026, primarily due to a new WLFI loan, compared to $1,544 for the same period in 2025 . #### Other Financial Metrics - Cash on hand was $10,500 as of March 28, 2026 . - The working capital deficit was approximately - $5,500 as of March 28, 2026, with total current liabilities of $39,100 and total current assets of $32,200 . - Cryptocurrency assets at fair value were $706,362 as of March 28, 2026 . ### Future Outlook and Strategy Janus Living, Inc. plans to raise funds through capital raises or structured arrangements, including capitalizing a subsidiary with biotechnology assets and acquiring an additional biotechnology asset . The company’s WLFI treasury program maintains a long-term “HODL” approach, with future acquisitions funded by operating cash flows, structured debt, and selective capital raises . Sales of WLFI tokens are restricted to liquidity requirements or material portfolio rebalancing events, acknowledging the significant market price risk associated with these tokens . ### Related Stocks - [JAN.US](https://longbridge.com/en/quote/JAN.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md) - [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md) - [Keysight Technologies Reports Second Quarter 2026 Results | KEYS Stock News](https://longbridge.com/en/news/286959830.md)